Evidence map›Paper›PMID 42049489›Full record

ArticleGut2026

Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability.

Sovanlal Mukherjee, Ajith Antony, Nandakumar G Patnam, Kamaxi H Trivedi, Aashna Karbhari, Khurram Khaliq Bhinder, Armin Zarrintan, Joel G Fletcher, Mark Truty, Matthew P Johnson and 2 more

Abstract read
In one paragraph

Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sovanlal MukherjeeDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Ajith AntonyDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Nandakumar G PatnamDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Kamaxi H TrivediDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Aashna KarbhariDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Khurram Khaliq BhinderDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Armin ZarrintanDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Joel G FletcherDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Mark TrutySurgery, Mayo Clinic, Rochester, Minnesota, USA.
Matthew P JohnsonQuantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Suresh T ChariGastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-3924-0971
Ajit Harishkumar GoenkaDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA goenka.ajit@mayo.edu.ORCID http://orcid.org/0000-0002-7804-2695

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid BiopsyR01CA256969 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Collisson, Ajit Harishkumar Goenka · 2021 to 2026
$3.1M
Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)R01CA272628 · NCI · MAYO CLINIC ROCHESTER · PI GOENKA, AJIT HARISHKUMAR · 2022 to 2025
$2.5M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA256969NCI NIH HHS R01 CA272628
6 · The paper itself

Abstract

backgroundFailure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary barrier to improving its otherwise poor rate of survival.

objectiveTo develop and validate the Radiomics-based Early Detection MODel (REDMOD), an AI framework to identify subvisual radiomic signatures of pre-diagnostic PDA on standard-of-care CT. DESIGNS: REDMOD was trained on a multi-institutional cohort (n=969; 156 pre-diagnostic, 813 control) and tested on an independent set (n=493; 63 pre-diagnostic, 430 control), simulating a low prevalence (~1:6) early detection paradigm. The fully automated framework couples AI-driven segmentation with a heterogeneous ensemble architecture trained on a 40-feature radiomic signature derived from Synthetic Minority Over-sampling Technique (SMOTE)-balanced data. A tunable Youden Index-optimised classification threshold enables performance calibration without retraining. Validation included direct comparison with radiologists, longitudinal test-retest analysis and external specificity validation across two independent cohorts (n=539 and n=80).

resultsOn an independent test set (n=493), REDMOD identified occult PDA (AUC 0.82; 73.0% sensitivity) at a median 475-day lead time. This represented nearly twofold higher sensitivity than radiologists (38.9%; p<0.001), which grew to nearly threefold (68.0% vs 23.0%) at >24 months lead time. REDMOD showed strong longitudinal stability (90-92% concordance) and generalisable specificity across multi-institutional (81.3%; n=539) and public (87.5%; n=80) datasets. Mechanistic analyses confirmed predictive power derived principally from multi-scale wavelet-filtered textural features (90% of selected signature), which outperformed unfiltered features (AUC 0.82 vs 0.74; p=0.007) in capturing subvisual architectural disruptions.

conclusionsREDMOD is an automated, mechanistically grounded, longitudinally stable, externally validated AI that surpasses radiologists for PDA detection at its visually occult pre-diagnostic stage. These attributes position it for prospective validation in high-risk cohorts, a necessary step towards shifting the paradigm from late-stage symptomatic diagnosis to proactive pre-clinical interception.

Indexed as

AI (Artificial Intelligence)IMAGINGPANCREASPANCREATIC CANCERPANCREATIC TUMOURS

Identifiers

PMID42049489
PMCPMC13242846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.